EP-104GI's Fibrosis Signal Is Intriguing but Unquantified; Competitive Clock Is Already Running

Eupraxia Reports Q2 2026 Financials and EP-104GI Clinical Progress

Eupraxia Pharmaceuticals announced its financial results for the second quarter of 2026, reporting a net loss of $14.5 million, an increase from $8.7 million in Q2 2025. The company maintains a strong financial position with $133.6 million in cash and short-term investments as of June 30, 2026, projected to fund operations into the second half of 2028. Eupraxia also highlighted new data for its lead candidate, EP-104GI, presented at Digestive Disease Week (DDW), demonstrating improvement in fibrosis and inflammation in Eosinophilic Esophagitis (EoE) patients. The company is preparing for a Phase 2b EoE trial with interim data expected in Q4, followed by a Phase 3 trial, and has strengthened its executive team and board to support late-stage development and commercialization.

• Financial Performance and Outlook: Eupraxia Pharmaceuticals reported a net loss of $14.5 million for Q2 2026, an increase from $8.7 million in Q2 2025, primarily due to higher research and development costs from doubling the RESOLVE Part 2 trial size, and increased general and administrative expenses. Despite this, the company maintains a strong financial position with $133.6 million in cash and short-term investments as of June 30, 2026, which is projected to fund operations into the second half of 2028, supporting upcoming clinical milestones.
• Clinical Progress in Eosinophilic Esophagitis (EoE): The company presented new data at Digestive Disease Week (DDW) for EP-104GI, demonstrating improvement in fibrosis and inflammation following a single treatment. Specifically, nine-month data from the highest dose cohort (Cohort 9, n=3) in the Phase 1b/2a RESOLVE trial showed the highest response in tissue health at week 36, with clinical remission in symptoms maintained in 66% of patients. This supports the potential for EP-104GI as an impactful and durable treatment option for EoE.
• Strategic Leadership and Future Development: Eupraxia has significantly strengthened its executive team and Board of Directors with key appointments, including a Chief Medical Officer and Executive Vice President of Technical Operations, along with three new industry leaders to the Board. These strategic hires are intended to bolster the company's capabilities for late-stage drug development and global commercialization of EP-104GI, as it prepares for a Phase 2b EoE trial with interim data in Q4 and plans for a subsequent Phase 3 trial and expansion into a broader GI portfolio in 2027.

EP-104GI's Promising Clinical Data in EoE RESOLVE Trial

The LIBERTY EoE TREET Trial (NCT03633617) evaluated subcutaneous dupilumab 300 mg weekly in adolescent and adult patients with eosinophilic esophagitis. At Week 24, dupilumab demonstrated statistically significant improvements over placebo across histologic, symptomatic, and endoscopic endpoints — including a reduction in peak intraepithelial eosinophil counts to ≤6 eos/hpf and meaningful absolute changes in Dysphagia Symptom Questionnaire (DSQ) scores. These efficacy gains were maintained through Week 52 and were observed regardless of prior swallowed corticosteroid use. The EoE KIDS Study (NCT04394351) extended this evidence to pediatric patients aged ≥1 to <12 years, using weight-tiered dosing designed to approximate the 300 mg weekly exposure seen in the TREET trial, and similarly demonstrated efficacy versus placebo in this younger population.

A real-world dupilumab study conducted at a single tertiary care center (January 2022 to October 2024) further corroborated these findings in routine clinical practice. Treated patients experienced significant reductions in clinical symptom and endoscopic scores, with peak eosinophil counts declining by a median of 47.5 eos/hpf. Histologic remission was achieved in 76.9% of patients at first follow-up and sustained in 72.7% at second follow-up. From a safety perspective, 15.9% of patients reported adverse events and 9.1% discontinued therapy — providing a practical benchmark for tolerability outside the controlled trial setting.

A Phase 2 multicenter, randomized, double-blind, placebo-controlled trial of budesonide oral suspension, conducted over 12 weeks in adolescents and adults aged 11–40 years, offered important insights into endpoint methodology alongside efficacy signals. The DSQ demonstrated capacity to detect symptom change over time, produced outcomes consistent with physician- and patient-rated measures, and correlated higher scores with greater esophageal eosinophilic burden. The trial established a minimal clinically important difference of –27.4% change in DSQ score, with a clinically important difference threshold of –55.4%, providing a validated and quantified framework for assessing symptomatic response in EoE trials.

Charting EP-104GI's Clinical Development Path in EoE

EP-104GI's development trajectory in EoE is informed by a growing body of pivotal trials that have established standardized endpoints across histologic, symptomatic, and endoscopic domains. The following trials represent the key clinical benchmarks shaping study design conventions in this indication, including co-primary endpoint structures and validated patient-reported outcome instruments.

Note on histologic thresholds: Across trials, histologic response is most commonly defined as ≤6 eos/hpf. However, evidence suggests that a threshold of <15 eos/hpf identifies most patients with symptom and endoscopic improvements, while a more stringent threshold of <5 eos/hpf is associated with combined symptomatic and endoscopic response.

Addressing Unmet Needs in Eosinophilic Esophagitis Treatment

Current treatment approaches for eosinophilic esophagitis (EoE) span dietary, pharmacological, and endoscopic modalities — yet each carries meaningful limitations that compromise long-term disease management. Across all therapeutic categories, the field continues to grapple with issues of durability, tolerability, and individualization, underscoring significant unmet clinical need.

• Dietary therapy is constrained by adherence, psychosocial burden, and nutritional risk. Extensive food elimination regimens are associated with poor patient and family compliance, the requirement for repeated endoscopic assessments, and the potential for nutrient deficiencies when long-term restrictions are applied. Exclusive elemental diets, while yielding the highest remission rates, are generally not recommended given their detrimental impact on quality of life. Allergy testing–guided dietary approaches further suffer from low reproducibility due to the poor accuracy of skin and serum tests in identifying EoE-specific food triggers.

• Topical corticosteroids demonstrate efficacy but carry practical and safety limitations. Swallowed formulations of fluticasone and budesonide require patients to refrain from eating or drinking for 45 minutes post-administration to optimize esophageal coating and anti-inflammatory effect. Candida esophagitis and oral candidiasis represent the most common adverse effects, and transient adrenal suppression has been documented — warranting ongoing cortisol monitoring with prolonged use. Critically, long-term safety data for both topical steroids and proton pump inhibitors remain insufficient.

• Relapse following treatment discontinuation is a defining challenge. EoE is a chronic, relapsing condition; symptomatic and histological remission achieved with PPIs or swallowed corticosteroids is frequently lost upon cessation of therapy. Although maintenance treatment appears clinically valuable, evidence from controlled studies with extended follow-up is lacking.

• Neither pharmacological nor endoscopic therapy addresses the full disease spectrum. Budesonide does not reverse established esophageal fibrosis, with fibrosis scores showing no significant improvement in treated patients. Endoscopic dilation, while safe and effective in fibrostenotic disease, does not reduce eosinophilic inflammation and is reserved for severe cases unresponsive to medical therapy.

• Diagnostic reliance on endoscopy and the absence of validated biomarkers limit precision management. Upper endoscopy with biopsy remains the diagnostic gold standard, but its invasiveness and cost are significant drawbacks. The lack of definitive non-invasive biomarkers complicates disease monitoring and hampers the development of personalized treatment strategies tailored to disease phenotype — whether allergic versus non-allergic or inflammatory versus fibrostenotic — as well as patient age, dietary habits, and available resources. Notably, no therapy has received regulatory approval specifically for EoE on a global basis.